Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
With their resistance to genotoxic and anti-proliferative drugs and potential to grow tumors and metastases from very few cells, cancer stem or tumor-initiating cells (TICs) are a severe limitation for the treatment of cancer by conventional therapies. Here, we explored whether human T cells that are redirected via an EpCAM/CD3-bispecific antibody called MT110 can lyse colorectal TICs and prevent tumor growth from TICs. MT110 recognizes EpCAM, a cell adhesion molecule expressed on TICs from diverse human carcinoma, which was recently shown to promote tumor growth through engagement of elements of the wnt pathway. MT110 was highly potent in mediating complete redirected lysis of KRAS-, PI3 kinase- and BRAF-mutated colorectal TICs, as demonstrated in a soft agar assay. In immunodeficient mice, MT110 prevented growth of tumors from a 5,000-fold excess of a minimally tumorigenic TIC dose. T cells engaged by MT110 may provide a potent therapeutic means to eradicate TICs and bulk tumor cells derived thereof.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, EpCAM/CD3 BiTEs eliminated CSCs in colon cancer cell lines and primary CSCs isolated from colon cancer patient samples and blocked CRC xenograft tumor growth [186,187].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [186]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Moreover, in colorectal cancer the presence of T cells in tumors correlates with survival of patients [50].”
BackgroundIdentification and expansion of human colon-cancer-initiating cells
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007) · Nature · doi:10.1038/nature05384 · Cited by 3,998 · cited 1×
“Moreover, independent reports showed expression of EpCAM on colorectal TICs [5,9,47,48], with evidence for a functional role of EpCAM in tumorigenesis [5,20].”
BackgroundCancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429 · cited 1×
“In order to verify their cancer stem cell phenotype, TICs were analyzed by FACS staining for expression of established surface markers [18], and by using RT-PCR for expression of mRNAs coding for surface and intracellular marker proteins.”
MethodIdentification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,523 · cited 1×
“Certain normal epithelial tissues and embryonic stem cells express EpCAM [24–26], but there is evidence to suggest that EpCAM on normal epithelial tissues is largely sequestered while it is accessible on the surface of cancer cells [27,28].”
BackgroundPhenotypic characterization of human colorectal cancer stem cells
Dalerba, P., Dylla, S. J., Park, I.-K., Liu, R., Wang, X., Cho, R. W., Hoey, T., Gurney, A., Huang, E. H., Simeone, D. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703478104 · Cited by 2,184 · cited 2×
“, from colorectal and pancreatic tumors, by using antibodies specific for epithelial cell adhesion molecule (EpCAM; also called ESA) [5,6].”
BackgroundTumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078 · cited 2×
“A CD19/CD3-bispecific BiTE antibody called blinatumomab showed high anti-tumor activity in relapsed non-Hodgkin’s lymphoma patients [40], providing clinical proof of concept for the therapeutic principle of BiTE antibodies.”
BackgroundSelf-citationPatrawala, L., Calhoun, T., Schneider-Broussard, R., Li, H., Bhatia, B., Tang, S., Reilly, J. G., Chandra, D., Zhou, J., Claypool, K., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209327 · Cited by 968 · cited 1×
“Furthermore, the expression of EpCAM and CD44 was shown to track with the tumorigenic phenotype of such cells [5,7– 10].”
BackgroundShmelkov, S. V., Butler, J. M., Hooper, A. T., Hormigo, A., Kushner, J., Milde, T., St. Clair, R., Baljevic, M., White, I., Jin, D. K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34401 · Cited by 896
Research works printed but not linked: 1
- R Kischel, 2009, Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110., AACR 2009 poster presentation
Cited by
Bispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2015) · Immunology & Cell Biology · doi:10.1038/icb.2014.93 · Cited by 466
EpCAM and its potential role in tumor-initiating cells
Imrich, S., Hachmeister, M., & Gires, O. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.18953 · Cited by 202
“Thus, combinations of several markers are more reliable to characterize cells as TICs.”
BackgroundInfluentialMolecular Biology of Liver Cancer Stem Cells
Oishi, N., Yamashita, T., & Kaneko, S. (2014) · Liver Cancer · doi:10.1159/000343863 · Cited by 169
Targeting T cells to tumor cells using bispecific antibodies
Frankel, S. R., & Baeuerle, P. A. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.03.029 · Cited by 166
Self-citationT cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Wu, Z., & Cheung, N. V. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.005 · Cited by 150
Metadata
- Authors
- Herrmann, I., Baeuerle, P. A., Friedrich, M., Murr, A., Filusch, S., Rüttinger, D., Majdoub, M. W., Sharma, S., Kufer, P., Raum, T., & Münz, M.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Baeuerle, Patrick A.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-10-18
- Volume
- 5
- Issue
- 10
- Pages
- e13474
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2956687
- OpenAlex
- W2024837280
- Cited by
- 85
- References
- 50
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 9 · 2019: 7 · 2018: 3 · 2017: 7 · 2016: 2 · 2015: 7 · 2014: 8 · 2013: 10 · 2012: 13
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- cancer stem cells, EpCAM, CD3, bispecific antibodies, T cell redirection, adoptive T cell therapy, tumor cell lysis, KRAS mutation, BRAF mutation, Wnt signaling
- MeSH terms
- Epithelial Cell Adhesion Molecule, Animals, Antigens, Neoplasm, Flow Cytometry, Humans, T-Lymphocytes, Colorectal Neoplasms, Cell Adhesion Molecules, Mice, SCID, Mice, Inbred NOD, CD3 Complex, Antibodies, Bispecific, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells. https://app.cochat.ai/papers/10.1371/journal.pone.0013474
- The paper
- Herrmann, I., Baeuerle, P. A., Friedrich, M., Murr, A., Filusch, S., Rüttinger, D., Majdoub, M. W., Sharma, S., Kufer, P., Raum, T., & Münz, M. (2010). Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells. PLoS ONE. https://doi.org/10.1371/journal.pone.0013474
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.